Growth parameters in HIV-vertically-infected adolescents on antiretroviral therapy in Rio de Janeiro, Brazil

Annals of Tropical Paediatrics

Volumn 28, Issue 1, 2008, Pages 59-64

  Buonora, Sibelle ^a   Nogueira, Susie ^a   Pone, Marcus Vinicius ^b   Aloé, Marisa ^c   Oliveira, Ricardo Hugo ^a   Hofer, Cristina ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Hospital Municipal Jesus   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY WEIGHT; BRAZIL; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; CHRONIC DIARRHEA; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROWTH DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; CHILD; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE TRANSMISSION; IMMUNOLOGY; MULTICENTER STUDY; VIROLOGY;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY HEIGHT; BODY WEIGHT; BRAZIL; CD4 LYMPHOCYTE COUNT; CHILD; DEVELOPING COUNTRIES; DISEASE TRANSMISSION, VERTICAL; FOLLOW-UP STUDIES; GROWTH DISORDERS; HIV INFECTIONS; HUMANS; RETROSPECTIVE STUDIES;

EID: 47549092784     PISSN: 02724936     EISSN: None     Source Type: Journal    
DOI: 10.1179/146532808X270699     Document Type: Article

References (21)

1. de Martino M, Tovo P-A, Balducci M, et al. Reduction in mortality with availability of therapy for children with perinatal HIV-1 infection. JAMA 2000; 284:190-7.
2. Mahoney EM, Donfield SM, Howard C, Kaufman F, Gertner JM. HIV-associated immune dysfunction and delayed pubertal development in a cohort of young hemophiliacs. Hemophilia Growth and Development Study. J Acquir Immune Defic Syndr 1999; 21:333-7.
3. Matarazzo P, Palomba E, Lala R, et al. Growth impairment, IGF I hyposecretion and thyroid dysfunction in children with perinatal HIV-1 infection. Acta Paediatr 1994; 83:1029-34.
4. Berhane R, Bagenda D, Marum L, et al. Growth failure as a prognostic indicator of mortality in pediatric HIV infection. Pediatrics 1997; 100:e7.
5. Laue L, Pizzo PA, Butler K, Cutler GB. Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome. J Pediatr 1990; 117:541-5.
6. van Rossum AMC, Gaakeer MI, Verweel G, et al. Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors. Pediatr Infect Dis J 2003; 22:70-6.
7. Arpadi SM, Cuff PA, Kotler DP, et al. Growth velocity, fat-free mass and energy intake are inversly related to viral load in HIV-infected children. J Nutr 2000; 130:2498-502.
8. McKinney RE Jr, Wilfert C. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine: AIDS Clinical Trials Group Protocol 043 Study Group. J Pediatr 1994; 125 (5 pt 1):728-33.
9. Newell MI, Borja MC, Peckham C. European Collaborative Study. Height, weight and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics 2003; 111:e52-60.
10. http://aidsinfo.nih.gov/guidelines/pediatric/PED_032405. pdf
11. Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43 (RR-12):1-10.
12. http://www.bcb.gov.br/?TXDOLAR.
13. Nachman SA, Lindsey JC, Moye J, et al. For the Pediatric AIDS Clinical Trials Group 377 Study Team. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2005; 24:352-7.
14. Verweel G. van Rossum AMC, Hartwig NG, et al. Treatment with highly active antiretroviral therapy in immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002; 109:1-7.
15. Miller TL, Mawn BE, Orav EJ, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics 2001; 107:e77.
16. Dreimane D, Nielsen K, Deveiks A, Bryson YJ, Geffner ME. Effect of protease inhibitors combined with standard therapy on linear growth and weight gain in human immunodeficiency virus type 1 -infected children. Pediatr Infect Dis J 2001; 20:315-16.
17. Nachman SA, Lindsey JC, Pelton S, et al. Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy. Arch Pediatr Adolesc Med 2002; 156:497-503.
18. Guillen S, Ramos JT, Resino R, Bellon JM, Munoz MA. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J 2007; 26:334-8.
19. Junqueira do Lago M, Faerstein E, de Souza Lopes C, Werneck GL. Pro-Saude Study (Rio de Janeiro, Brazil). Family socio-economic background modified secular trends in age at menarche: Evidence from the Pro-Saude Study (Rio de Janeiro, Brazil). Ann Hum Biol 2003; 30:347-52.
20. Buchacz K, Rogol AD, Lindsey JC, et al. Pediatric AIDS Clinical Trials Group 219 Study Team. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr 2003; 33:56-65.
21. de Martino M, Tovo PA, Galli L, et al. Puberty in perinatal HIV-1 infection: A multicentre longitudinal study of 212 children. AIDS 2001; 15:1527-34.